|1.||Waddell, David D: 11 articles (06/2015 - 01/2003)|
|2.||Bellamy, N: 7 articles (12/2007 - 07/2002)|
|3.||Chevalier, X: 4 articles (06/2013 - 09/2003)|
|4.||Conrozier, Thierry: 4 articles (07/2008 - 03/2003)|
|5.||Granata, Mauro: 4 articles (05/2008 - 06/2005)|
|6.||Tormenta, Sandro: 4 articles (05/2008 - 06/2005)|
|7.||Massafra, Umberto: 4 articles (05/2008 - 06/2005)|
|8.||Migliore, Alberto: 4 articles (05/2008 - 06/2005)|
|9.||Alimonti, Andrea: 4 articles (05/2008 - 06/2005)|
|10.||Tugwell, P: 4 articles (06/2005 - 07/2002)|
12/01/2011 - "The Hylan G-F 20 group showed a significant pain reduction (P < 0.05), improvement in the Constant-Murley, SPADI scores (P < 0.05), and satisfaction (P < 0.01) at all three follow-up times. "
08/01/2008 - "Improvement in the WOMAC pain subscale was significantly superior in the Hylan G-F 20 group at 3 months (p=0.02), 6 months (p=0.01) and 12 months (p=0.007). "
04/01/2008 - "Hylan G-F 20 may be more beneficial for those patients who desire to increase their activity level rather than those who wish to decrease their pain. "
08/01/2008 - "Knee pain on VAS improved from 6.7 to 3.2 by 6 weeks (p=0.02) and was sustained until 12 months (3.7, p=0.04) with Hylan G-F 20. "
05/01/2011 - "F60027 and Hylan G-F20 were equally effective in reducing functional impairment and relieving pain in KOA patients, and well-tolerated."
10/01/2009 - "Hylan G-F 20 significantly improved Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) physical function versus appropriate/conventional care or corticosteroid, it significantly improved loss of activity versus saline, and it had similar functional improvements compared with progressive knee exercises or nonsteroidal anti-inflammatory drugs. "
01/01/2006 - "Patients (n=1047; 1489 knees) were an average age of 65.3 years, 60% female, and 71% had radiologic osteoarthritis grade IV. Mean VAS scores significantly improved with hylan G-F 20 compared to baseline at all time points (P<.0001). "
01/01/2008 - "Hylan G-F 20 is well-tolerated and effective for up to 6 months in the treatment of symptomatic ankle osteoarthritis."
08/01/2003 - "To study the efficacy of hylan G-F 20 in the treatment of osteoarthritis (OA) of the hip joint. "
12/01/2009 - "To evaluate the feasibility, safety, and symptomatic efficacy of intra-articular Hylan G-F 20 in patients with shoulder osteoarthritis and an intact rotator cuff. "
01/01/2003 - "Hylan G-F 20 was safe and effective in knee osteoarthritis and had a relatively low cost-utility ratio."
04/01/2008 - "The purpose of this study was to evaluate the efficacy of hylan G-F 20 when used to treat an active and athletic patient population with knee osteoarthritis who had undergone knee arthroscopy for mechanical symptoms. "
01/01/2014 - "Long-Term (1-Year) Safety and Efficacy of a Single 6-mL Injection of Hylan G-F 20 in Indian Patients with Symptomatic Knee Osteoarthritis."
10/01/2009 - "Functional improvement with hylan G-F 20 in patients with knee osteoarthritis."
02/01/2005 - "To compare the effectiveness and safety of repeat treatment with hylan G-F 20 based on data from a randomized, controlled trial [Raynauld JP, Torrance GW, Band PA, Goldsmith CH, Tugwell P, Walker V, et al. A prospective, randomized, pragmatic, health outcomes trial evaluating the incorporation of hylan G-F 20 into the treatment paradigm for patients with knee osteoarthritis (Part 1 of 2): clinical results. "
|4.||Hip Osteoarthritis (Coxarthrosis)
06/01/2010 - "Hylan g-f 20 improves hip osteoarthritis: a prospective, randomized study."
05/01/2008 - "This prospective, observational, open study aimed to assess the efficacy and safety of hylan G-F 20 in a large cohort of patients with symptomatic hip osteoarthritis (OA), and identify predictors of clinical response. "
05/01/2008 - "Intra-articular administration of hylan G-F 20 in patients with symptomatic hip osteoarthritis: tolerability and effectiveness in a large cohort study in clinical practice."
03/01/2008 - "We prospectively included patients scheduled for intraarticular Hylan GF-20 injection to treat hip osteoarthritis. "
03/01/2008 - "To evaluate the influence of a joint effusion on the clinical response to a single injection of Hylan GF-20 for hip osteoarthritis. "
10/01/2009 - "Hylan G-F 20 should be considered as part of a multimodal arthritis treatment regimen that focuses on improving function."
01/01/2008 - "Hylan versus corticosteroid versus placebo for treatment of basal joint arthritis: a prospective, randomized, double-blinded clinical trial."
01/01/2014 - "Clinicians recommending therapeutic Hylan injections for the management of hip arthritis should maintain clinical awareness regarding this potential complication. "
10/01/2012 - "A single intraarticular injection of both hylan G-F 20 and HA for primary knee arthritis had no adverse event related to 6-ml volume. "
01/01/2008 - "Sixty patients with basal joint arthritis were randomized to receive 2 intra-articular hylan injections 1 week apart, 1 placebo injection followed by 1 corticosteroid injection 1 week later, or 2 placebo injections 1 week apart. "
|2.||Hyaluronic Acid (Hyaluronan)
|3.||Adrenal Cortex Hormones (Corticosteroids)
|4.||Collagen Type II (Type II Collagen)
|7.||Prostaglandins A (PGA)
|8.||Interleukin-1 (Interleukin 1)
|10.||betamethasone sodium phosphate
|4.||Self-Help Devices (Assistive Technology)